Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2019 16:05 ET | Source: Pfenex, Inc.

Pfenex Licensee Successfully Completes a Phase 3 Study and Enters Registration for Pneumosil®

SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (SIIPL), has completed a pivotal Phase 3 study for...
March 04, 2019 08:05 ET | Source: Pfenex, Inc.

Pfenex Announces Appointment of New Board Member, Magda Marquet, Ph.D.

SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
February 28, 2019 08:05 ET | Source: Pfenex, Inc.

Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo®/Forsteo®, to the EU, MENA, and ROW

SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) and Alvogen Ltd. today announced entering into agreements expanding their collaboration to develop and commercialize...
February 27, 2019 16:05 ET | Source: Pfenex, Inc.

Pfenex to Participate at Two Investor Conferences in March

SAN DIEGO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
February 25, 2019 16:05 ET | Source: Pfenex, Inc.

Pfenex to Host Conference Call and Webcast Reporting Fourth Quarter Financial Results on Monday, March 11th

SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression...
February 19, 2019 08:05 ET | Source: Pfenex, Inc.

Pfenex Announces FDA Acceptance of NDA for PF708

SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the 505(b)(2) New Drug...
December 10, 2018 08:00 ET | Source: Pfenex, Inc.

Pfenex Submits New Drug Application to U.S. FDA Seeking Approval of PF708 for the Treatment of Osteoporosis

SAN DIEGO, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking...
November 07, 2018 16:05 ET | Source: Pfenex, Inc.

Pfenex Reports Third Quarter Results and Provides Business Update

On track to submit the NDA for PF708 to the FDA in fourth quarter of 2018 SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and...
October 25, 2018 16:05 ET | Source: Pfenex, Inc.

Pfenex to Host Conference Call and Webcast Reporting Third Quarter Financial Results on Wednesday, November 7

SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE AMERICAN: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression...
October 01, 2018 16:05 ET | Source: Pfenex, Inc.

Pfenex Reports New Employment Inducement Award Under NYSE American Listing Rules

SAN DIEGO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) (“Pfenex” or the “Company”), a clinical-stage development and licensing biotechnology company focused on leveraging its...